E. Richardet

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

D. Carbone, E. Felip, T. John, 2021, ESMO open.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

D. Carbone, E. Felip, L. Paz-Ares, 2021, The Lancet. Oncology.

Irinotecan, Oxaliplatin Plus Bolus 5-Fluorouracil and Low Dose Folinic Acid Every 2 Weeks: A Feasibility Study in Metastatic Colorectal Cancer Patients

E. Richardet, F. Cóppola, Claudio Martín, 2006, American journal of clinical oncology.

HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America

R. Bezares, E. Richardet, N. Duma, 2022, JCO global oncology.

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2020 .

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Joaquim Bellmunt, Enrique Gallardo, Fred Saad, 2013, The Lancet. Oncology.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

E. Perez, C. Sotiriou, S. Loi, 2021, NPJ breast cancer.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

M. Provencio, J. Penrod, F. Franke, 2019, European journal of cancer.

Melanoma: oncogenic drivers and the immune system.

R. Rosell, M. Santarpia, S. Pilotto, 2015, Annals of translational medicine.

Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America

I. Wistuba, F. Hirsch, C. Vallejos, 2017, Clinical lung cancer.

Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.

J. R. Pereira, M. Orlando, G. Schwartsmann, 2007, Lung cancer.

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.

M. Rizzo, G. Recondo, R. Kowalyszyn, 2020, Clinical lung cancer.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

PSA values as a surrogate of overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC) treated with second-line (2L) chemotherapy (CT).

M. Molina, E. Richardet, A. Riso, 2014 .

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.

M. Vilanova, E. Cazap, G. Recondo, 2001, European journal of cancer.

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2021 .

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy.

S. Agrawal, T. Mekhail, D. Spigel, 2016, Journal of Thoracic Oncology.

Outcomes in Latin American NSCLC patients harboring wild-type or activating mutations of EGFR (CLICaP Registry).

R. Rosell, A. Campos-Parra, O. Arrieta, 2012 .

Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina.

E. Richardet, P. X. de la Iglesia, D. Enrico, 2018, Annals of diagnostic pathology.

Uracil/tegafur plus oral calcium folinate in advanced breast cancer.

L. Fein, G. Lerzo, E. Richardet, 1999, Oncology.

OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC

M. Provencio, J. Penrod, F. Franke, 2018, Journal of Thoracic Oncology.

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

N. Reinmuth, Ying Cheng, T. John, 2023, Journal of Clinical Oncology.

Gemcitabine (GEM) + oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): Preliminary report of a phase II study.

M. Orlando, G. Lerzo, E. Richardet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Ying Cheng, D. Carbone, L. Paz-Ares, 2020 .